NLS Pharmaceutics AG
NLSP
$1.47
-$0.053-3.48%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.83% | -20.10% | -9.33% | -3.75% | 1.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -56.00% | -39.25% | -23.74% | -16.95% | -10.38% |
| Operating Income | 56.00% | 39.25% | 23.74% | 16.95% | 10.38% |
| Income Before Tax | 57.36% | 41.29% | 26.21% | 14.90% | 3.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.36% | 41.29% | 26.21% | 14.90% | 3.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.36% | 41.29% | 26.21% | 14.90% | 3.23% |
| EBIT | 56.00% | 39.25% | 23.74% | 16.95% | 10.38% |
| EBITDA | 56.05% | 39.28% | 23.76% | 16.96% | 10.40% |
| EPS Basic | 68.55% | 65.53% | 63.70% | 57.33% | 52.33% |
| Normalized Basic EPS | 66.05% | 63.50% | 62.00% | 58.48% | 55.84% |
| EPS Diluted | 68.55% | 65.53% | 63.70% | 57.33% | 52.33% |
| Normalized Diluted EPS | 66.05% | 63.50% | 62.00% | 58.48% | 55.84% |
| Average Basic Shares Outstanding | 29.96% | 54.90% | 93.96% | 102.97% | 115.34% |
| Average Diluted Shares Outstanding | 29.96% | 54.90% | 93.96% | 102.97% | 115.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |